EUVIMEDEUVIMED entdecken
Crossref

Mifepristone reduces serum cancer antigen 125 and prolactin levels to improve pregnancy rates in uterine adenomyosis mouse models

Chuyu Peng, Yan Zeng, Ling Zhao, Zhenqin Gao, Liumei Luo, Shanshan Ou, Yingdan Huang, Bo Liu iD

Biology of Reproduction · 2026

DOI: 10.1093/biolre/ioag017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biology of Reproduction, 2026. Verfasst von Chuyu Peng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center of Reproductive Medicine, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China. Hauptthemen laut MEDLINE: Mifepristone, Adenomyosis, Prolactin, CA-125 Antigen. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Guangxi Natural Science Foundation Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Uterine adenomyosis is a widespread condition that impairs female fertility, with elevated serum levels of cancer antigen 125 (CA125) and prolactin (PRL) often observed in affected women. Mifepristone has been investigated as a potential therapeutic agent to improve pregnancy outcomes in uterine adenomyosis patients. This study aimed to examine the effects of mifepristone on serum CA125 and PRL levels in uterine adenomyosis mouse models. The Institute of Cancer Research (ICR) mice were treated with varying doses of mifepristone after uterine adenomyosis was induced. Immunohistochemistry was used to analyze estrogen receptor and CA125 expression in uterine tissues, while serum CA125 and PRL levels were measured by enzyme-linked immunosorbent assay (ELISA). The study found that mifepristone treatment significantly reduced serum CA125 and PRL levels, and the 20 mg/kg/day dose was most effective in improving pregnancy outcomes. These findings suggest that mifepristone can reduce key biomarkers associated with uterine adenomyosis and improve fertility outcomes, offering a promising treatment option for women suffering from this condition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MifepristoneAdenomyosisProlactinCA-125 AntigenHormone AntagonistsAnimalsFemalePregnancyMiceDisease Models, AnimalMice, Inbred ICR

Stichwörter der Autor:innen

CA125estrogen receptorinfertilitymifepristoneprolactinuterine adenomyosis

Substanzen

MifepristoneProlactinCA-125 AntigenHormone Antagonists

Autor:innen und Institutionen

  • Center of Reproductive Medicine, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
  • Department of Pathology, Zhuzhou Hospital Affiliated to Xiangya Medical College, Central South University, Changsha, China.

ORCID-Profile: Bo Liu

Förderung

  • Guangxi Natural Science Foundation Project

Zitieren

APA

Peng, C., Zeng, Y., Zhao, L., Gao, Z., Luo, L., Ou, S., Huang, Y., & Liu, B. (2026). Mifepristone reduces serum cancer antigen 125 and prolactin levels to improve pregnancy rates in uterine adenomyosis mouse models. Biology of Reproduction. https://doi.org/10.1093/biolre/ioag017

Vancouver

Peng C, Zeng Y, Zhao L, Gao Z, Luo L, Ou S, et al. Mifepristone reduces serum cancer antigen 125 and prolactin levels to improve pregnancy rates in uterine adenomyosis mouse models. Biology of Reproduction. 2026. doi:10.1093/biolre/ioag017

BibTeX
@article{Peng2026,
  author = {Peng, Chuyu and Zeng, Yan and Zhao, Ling and Gao, Zhenqin and Luo, Liumei and Ou, Shanshan and Huang, Yingdan and Liu, Bo},
  title = {Mifepristone reduces serum cancer antigen 125 and prolactin levels to improve pregnancy rates in uterine adenomyosis mouse models},
  journal = {Biology of Reproduction},
  year = {2026},
  doi = {10.1093/biolre/ioag017}
}
Kostenlos starten →